Comparing Ascendis Pharma A/S (NASDAQ:ASND) & Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.

Profitability

This table compares Taysha Gene Therapies and Ascendis Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Earnings and Valuation

This table compares Taysha Gene Therapies and Ascendis Pharma A/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77 million	133.73	-$109.00 million	($0.42)	-9.55
Ascendis Pharma A/S	$814.57 million	18.61	-$258.00 million	$12.89	18.85

Taysha Gene Therapies has higher earnings, but lower revenue than Ascendis Pharma A/S. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Taysha Gene Therapies and Ascendis Pharma A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1	0	12	2	3.00
Ascendis Pharma A/S	0	1	18	1	3.00

Taysha Gene Therapies currently has a consensus target price of $12.77, suggesting a potential upside of 218.43%. Ascendis Pharma A/S has a consensus target price of $309.26, suggesting a potential upside of 27.27%. Given Taysha Gene Therapies’ higher probable upside, research analysts clearly believe Taysha Gene Therapies is more favorable than Ascendis Pharma A/S.

Summary

Ascendis Pharma A/S beats Taysha Gene Therapies on 8 of the 14 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.